Max Healthcare: Strong Q2 Performance, Strategic Expansion, and Attractive Valuations Signal Growth Potential

Overview

Max Healthcare reported robust Q2FY26 results with significant growth in revenue and EBITDA. The company saw a 58% jump in net profit, partly due to a favorable tax gain from the merger of JHL and CRL. Bed capacity expanded across multiple locations, and plans are on track to add approximately 3,000 beds through brownfield projects. The stock's current valuation at ~24x FY28e EV/EBITDA is considered attractive for entry, trading at a discount to its 5-year average.